Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is <100mg/dl for patients with high risk and <70mg/dl for patients at very high risk) are screened (office-based specialists). The doctors therapy decisions after the screening and possible reasons for these decisions will be documented. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hyperlipidemias Arterial Occlusive Diseases Arteriosclerosis Atherosclerosis Brain Diseases Cardiovascular Diseases Carotid Artery Diseases Carotid Stenosis Central Nervous System Diseases Cerebrovascular Disorders Coronary Disease Coronary Heart Disease Diabetes Mellitus Dyslipidemias Endocrine System Diseases Glucose Metabolism Disorders Heart Diseases Lipid Metabolism Disorders Metabolic Diseases Myocardial Ischemia Nervous System Diseases Nutritional and Metabolic Diseases Peripheral Vascular Diseases Vascular Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site

Vienna, Austria

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes who already receive cholesterol-lowering therapy

Exclusion criteria

Patients who do not receive cholesterol-lowering therapy

Treatment and study plan

Primary outcomes

Lipid profile

Time frame: At screening and 8-5 weeks after screening
HbA1c profile

Time frame: At screening and 8-5 weeks after screening

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Non-interventional Study Investigating How Effective Secondary Prevention Patients Are Treated to Their LDL-C Targets

Important dates

Study start: 2007
Primary completion: 2007
Study completion: 2007
First posted: Sep 28, 2007
Registry last updated: Oct 30, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed